Luncolive Saving Cardiac Arrest Patients with Hypothermic Lung Conservative Liquid Ventilation

Summary

Orixha offers a major clinical breakthrough in Critical Care with its unique LUNg COnservative LIquid VEntilation (hence LuncoLive) technology. It powers the Vent2Cool medical device to induce ultra-rapid protective cooling of heart and brain of resuscitated cardiac arrest patients. Vent2Cool will increase their survival rate by tackling the reperfusion injury of Post Cardiac Arrest Syndrome .
LuncoLive project will enable clinical validation of Vent2Cool as a new gold standard for post-resuscitation care. Orixha will industrialize and miniaturize the technology to increase usability as well as reduce costs and environmental impact, in particular through recycling of the Liquid2Breathe breathable liquid. Its success will enable Orixha to market the first Vent2Cool devices in the EU by 2026 and reach profitability by 2028. It will also strengthen Orixha's ability to develop future applications for respiratory support and pre-hospital emergency care.

Resources

Show all and search (1)

Unfold all

Fold all

More information & hyperlinks

Web resources:	https://cordis.europa.eu/project/id/190172852
Start date:	01-05-2023
End date:	30-04-2026
Total budget - Public funding:	3 516 062,50 Euro - 2 449 869,00 Euro

Cordis data

Original description

Orixha offers a major clinical breakthrough in Critical Care with its unique LUNg COnservative LIquid VEntilation (hence LuncoLive) technology. It powers the Vent2Cool medical device to induce ultra-rapid protective cooling of heart and brain of resuscitated cardiac arrest patients. Vent2Cool will increase their survival rate by tackling the reperfusion injury of Post Cardiac Arrest Syndrome .
LuncoLive project will enable clinical validation of Vent2Cool as a new gold standard for post-resuscitation care. Orixha will industrialize and miniaturize the technology to increase usability as well as reduce costs and environmental impact, in particular through recycling of the Liquid2Breathe breathable liquid. Its success will enable Orixha to market the first Vent2Cool devices in the EU by 2028 and reach profitability by 2030. It will also strengthen Orixha's ability to develop future applications for respiratory support and pre-hospital emergency care.